Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial

Mar 30, 2026

News

FDA Grants Fast Track to Coramitug for ATTR-CM, Supporting Amyloid-Clearing Phase 3 Trial

Apr 28, 2026

EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

Apr 28, 2026

Quantitative imaging in cardiac transthyretin amyloidosis: rationale and design of the i-CARE study

Apr 28, 2026

FDA grants fast track status to Novo Nordisk’s ATTR-CM drug

Apr 27, 2026

Study Finds Less Advanced Disease in Recent ATTR-CM Trials

Apr 27, 2026

More in News

Education

The Cardiac Amyloidosis Revolution: How ATTR Therapies Are Rewriting Heart Failure Treatment in 2026

Apr 18, 2026

ACC CardiaCast: ATTR-CM Treatment: Recent Updates

Apr 17, 2026

How ATTR amyloidosis can progress over time

Apr 15, 2026

How ATTR amyloidosis can progress over time

Apr 15, 2026

Real-world Experience with Tafamidis in patients with Cardiac Amyloidosis

Apr 15, 2026

More in Education

Community Center

Radcliffe Cardiology

Apr 28, 2026

ATTR-cardiac amyloidosis (ATTR-CM)

Apr 28, 2026

National Ataxia Foundation

Apr 16, 2026

Amyloidosis Support Group Meeting

Apr 15, 2026

Cardiac Amyloidosis: A Hidden Cause of Heart Failure Is Now Treatable

Apr 15, 2026

More in Community Center

Video